Cyclo Therapeutics Inc. [NASDAQ: CYTH] gained 18.81% on the last trading session, reaching $13.33 price per share at the time. The company report on February 9, 2021 that Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021.
Data from ongoing Phase 1 extension study shows improvement in disease features or disease stabilization with home-based intravenous infusions of Trappsol® Cyclo™.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Phase 1 biomarker 24S-hydroxycholesterol demonstrates clearance of excess cholesterol from the brain after intravenous infusions.
Cyclo Therapeutics Inc. represents 151.95 million in outstanding shares, while the company has a total market value of $77.18 million with the latest information. CYTH stock price has been found in the range of $12.10 to $17.75.
If compared to the average trading volume of 1.39M shares, CYTH reached a trading volume of 4964758 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Cyclo Therapeutics Inc. [CYTH]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CYTH shares is $12.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CYTH stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Cyclo Therapeutics Inc. is set at 1.71, with the Price to Sales ratio for CYTH stock in the period of the last 12 months amounting to 77.18.
Trading performance analysis for CYTH stock
Cyclo Therapeutics Inc. [CYTH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 79.41. With this latest performance, CYTH shares gained by 163.96% in over the last four-week period, additionally plugging by 2.54% over the last 6 months – not to mention a drop of -24.05% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CYTH stock in for the last two-week period is set at 72.23, with the RSI for the last a single of trading hit 75.54, and the three-weeks RSI is set at 72.72 for Cyclo Therapeutics Inc. [CYTH], while it was recorded at 11.27 for the last single week of trading.
Cyclo Therapeutics Inc. [CYTH]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Cyclo Therapeutics Inc. [CYTH] shares currently have an operating margin of -749.06 and a Gross Margin at -97.34. Cyclo Therapeutics Inc.’s Net Margin is presently recorded at -747.87.
Return on Total Capital for CYTH is now -714.76, given the latest momentum, and Return on Invested Capital for the company is -719.20. Return on Equity for this stock declined to -731.82, with Return on Assets sitting at -210.37. When it comes to the capital structure of this company, Cyclo Therapeutics Inc. [CYTH] has a Total Debt to Total Equity ratio set at 5.61. Additionally, CYTH Total Debt to Total Capital is recorded at 5.31, with Total Debt to Total Assets ending up at 1.28. Long-Term Debt to Equity for the company is recorded at 3.86, with the Long-Term Debt to Total Capital now at 3.65.
Reflecting on the efficiency of the workforce at the company, Cyclo Therapeutics Inc. [CYTH] managed to generate an average of -$941,567 per employee. Receivables Turnover for the company is 6.72 with a Total Asset Turnover recorded at a value of 0.28.Cyclo Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.90.
An analysis of insider ownership at Cyclo Therapeutics Inc. [CYTH]
Positions in Cyclo Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 0 institutional holders increased their position in Cyclo Therapeutics Inc. [NASDAQ:CYTH] by around 0 shares. Additionally, 1 investors decreased positions by around 300 shares, while 1 investors held positions by with 200 shares. The mentioned changes placed institutional holdings at 100 shares, according to the latest SEC report filing. CYTH stock had 0 new institutional investments in for a total of 0 shares, while 1 institutional investors sold positions of 300 shares during the same period.